Quick Answer
Xilio Therapeutics, Inc. reported Operating Income Loss of -$41.98 million for the year ending 2025.
- Xilio Therapeutics, Inc. showed an increase of +30.7% in Operating Income Loss from 2024 to 2025.
- This data is from Xilio Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: -$14.62 million | Q1 2021: -$16.52 million | Q2 2021: -$23.01 million | Q3 2021: -$15.96 million | Q1 2022: -$21.22 million | Q2 2022: -$24.55 million | Q3 2022: -$20.21 million | Q1 2023: -$23.53 million | Q2 2023: -$20.12 million | Q3 2023: -$17.36 million | Q1 2024: -$17.49 million | Q2 2024: -$14.70 million | Q3 2024: -$14.76 million | Q1 2025: -$13.85 million | Q2 2025: -$14.37 million | Q3 2025: -$1.93 million.
- Over the full 6 years of available data (2020 to 2025), Xilio Therapeutics, Inc.'s Operating Income Loss has grown by 23.1%.
- Historical annual values: Fiscal year 2025: -$41.98 million | Fiscal year 2024: -$60.58 million | Fiscal year 2023: -$79.13 million | Fiscal year 2022: -$89.15 million | Fiscal year 2021: -$75.04 million | Fiscal year 2020: -$54.56 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: